Effectiveness and Efficiency of Mobile Technology in Disease Control and Healthy Lifestyle Promotion in Asthmatic Overweight/Obese Patients. A Pilot Study.
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Change in % of Forced Expiratory Volume in the first second (FEV1) from baseline to endpoint
研究概览
简要总结
Single-center open-label randomized pilot study to assess the effectiveness and efficiency of a mobile technology based intervention for asthma and obesity control.
详细描述
Single-center open-label randomized pilot study to assess the effectiveness and efficiency of a mobile technology based intervention for asthma and obesity control. The interventional group subjects received a mobile device with an ad-hoc designed application (called ASMATIC) which permitted them to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and advice for healthy lifestyle habits, including personalized diet recommendations and exercise monitoring. The device also permits a bidirectional communication between the patient and the study staff for reporting any emerging issues related to the asthmatic condition of the patient, as the need of additional in-personconsultations. The control group is followed-up based on the study site usual clinical practice, without any specific intervention.
The primary study objective is to evaluate whether the use of the ASMATIC mobile application use improves parameters of asthma control, obesity control, asthma obese patient's quality of life and if it's associated with savings in health-related costs (efficiency assessment), compared to the usual clinical practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 y.o. or more.
- •Diagnosis of asthma, confirmed by spirometry: positive post bronchodilator test (PBT), defined as an improvement of at least 12% and an increment of at least 200 ml in the absolute value of FEV1 following B-agonist inhalation. In case of negative PBT, asthma diagnoses could be establish if a positive result, defined as a PC20< 8 pgr, was achieved in the Methacholine Challenge Test (MCT).
- •BMI of 25 or more.
- •Subjects must meet criteria of acceptability of spirometry in at least in three manoeuvres (within a maximun of 8). Acceptability of a spirometry for this protocol purpose is defined by: a) minimum of 6 second exhalation time; b) no cough detected in the first second of expiration; c) 1 second volume plateau.
- •Subjects must meet criteria of repeatability of spirometry, defined for this protocol purpose as the three highest accepted FEV1 values to be within 0.10L (100mL) of each other or with a variability of 5% or less.
- •Subjects with capacity to handle a smartphone device, with incorporated Android system, and to use and input data on the app ASMATIC, designed for this study purposes.
- •Subjects willing to give voluntary, signed informed consent, in accordance with Good Clinical Practice (GCP) guidelines.
排除标准
- •Subjects with uncontrolled or severe asthma at study entry, defined by at least one of the following criteria: a) FEV1 <80% of the theorical calculated value and a FEV1/FVC ratio <75% at study entry; b) any severe asthma exacerbation within the two months previous to study entry; c) systemic corticoid or any biological treatment received in the previous 6 months to study entry.
- •Any known contraindication for bronchodilator reversibility testing or bronchial provocation tests such us: a) any respiratory tract infection in the previous month to selection; b) pregnancy, lactation or intention to become pregnant during the study; or c) any other contraindication for spirometry found following clinical criteria.
- •Subjects with any limitation in their capacity to collaborate and comply with study requirements.
- •Active smokers or ex-smokers in the 6 months previous to study entry.
- •Subjects currently in immunotherapy treatment or potential candidates for it, including subject suffering a malignant disease.
- •Subjects with asthma non controlled risk factors.
- •Subjects with any severe or non controlled pathology that compromise their safety during their participation study.
结局指标
主要结局
Change in % of Forced Expiratory Volume in the first second (FEV1) from baseline to endpoint
时间窗: 1 year
Asthma control assessed through the change in % FEV1 from baseline to endpoint in the interventional group and between the interventional and control groups.
次要结局
- Change in % FEV1 from baseline to weeks 8 and 24.(6 months)
- Change in the Tiffenau index (FEV1/FVC (Forced Vital Capacity) from baseline to endpoint.(1 year)
- Change in the Tiffenau index (FEV1/FVC) from baseline to weeks 8 and 24.(6 months)
- Changes in the Asthma Quality of Life Questionnaire (AQLQ) score from baseline to endpoint(1 year)
- Mean number of days of rescue medication use.(1 year)
- Change in number of Quality-Adjusted Life Years (QALYs) from baseline to endpoint.(1 year)
- Change in the Body Mass Index (BMI) (measured in kg/m^2) from baseline to endpoint(1 year)
- Change in abdominal perimeter (measured in cm) from baseline to endpoint(1 year)
- Change in neck perimeter (measured in cm) from baseline to endpoint (in male study subjects).(1 year)
- Change in hip perimeter (measured in cm) from baseline to endpoint (in female study subjects).(1 year)
- Total healthcare costs of the consultations in ER, Primary Care and Allergology Service related to the asthmatic condition reported by the patients during the whole study period (measured in euros)(1 year)
- Healthcare costs of the mean ER consultations related to asthmatic symptoms exacerbation reported by the study subjects during the whole study (measured in euros)(1 year)
- Healthcare costs of Primary Care consultations related to asthmatic symptoms exacerbation reported by the study subjects during the whole study (measured in euros)(1 year)
- Healthcare costs of consultations with the Allergologist (measured in euros)(1 year)